NCT02223988

Brief Summary

Ventilator-associated pneumonia (VAP) is a serious complication and carries increased risks of morbidity and mortality for patients who require mechanical ventilation. VAP is associated with the contamination and colonization of bacteria in the lower airway. These bacteria may be present in the lower airway by the aspiration of oropharyngeal secretions. Therefore limiting the amount of secretions that pass the glottis and enter the airway is paramount. Patients who require prolonged mechanical ventilation may have a tracheostomy tube placed to manage breathing. These tubes may have a distal cuff which sits within the trachea. When the cuff is inflated, oropharyngeal secretions will pool above the cuff of the tracheostomy tube thereby limiting the amount of secretions entering the lower airway. These secretions may leak around the cuff and cause tracheobronchial colonization. It has been shown that removal of secretions that pool above the cuff via dorsal lumen suction leads to a decreased incidence of VAP. The purpose of this study is to measure the effect of suction above the cuff tracheostomy tubes related to VAP incidence

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 21, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 22, 2014

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

May 9, 2017

Status Verified

May 1, 2017

Enrollment Period

1.9 years

First QC Date

August 21, 2014

Last Update Submit

May 5, 2017

Conditions

Keywords

Patientsmechanicalventilationtracheostomy

Outcome Measures

Primary Outcomes (1)

  • Incidence of VAP

    at 28 days

Secondary Outcomes (4)

  • Mortality rate

    at 28 days

  • Duration of mechanical ventilation

    30 days

  • ICU length of stay

    30 days

  • Ventilator free days after tracheostomy

    28 days

Study Arms (1)

subglottic secretion drainage

EXPERIMENTAL
Procedure: subglottic secretion removal

Interventions

subglottic secretion drainage

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients on mechanical ventilation for respiratory failure for at least 72 hours.
  • A score of 35 to 65 on the Simplified Acute Physiology Score II (SAPS II).
  • Does not have a pulmonary infection estimated by a Clinical Pulmonary Infection Score (CPIS).
  • Age \>= 18 years.

You may not qualify if:

  • A history of esophageal, tracheal or pulmonary cancer or an existing malignancy within the trachea at the tracheostomy site.
  • Previous surgery at the tracheostomy site (e.g. thyroidectomy).
  • Bleeding diathesis (e.g. due to anticoagulation therapy).
  • Emergency surgical airway management.
  • Morbid obesity and/or neck edema (skin to trachea distance may render tracheostomy tube too short).
  • Pre-existing infection at the tracheostomy site.
  • Uncertainty in identifying the anatomical landmarks.
  • Patients with a do not resuscitate order.
  • Immunosuppressed and/or immunodepressed patients (Immunodepression being defined by the following conditions: 1-Leukocytes \< 1000/µl, 2-Neutrophils \< 500/µl. 3-AIDS Long-term steroid treatment (daily dose \> 0.5 mg/kg) for more than 30 days)
  • Patients already enrolled in other trials

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Turin - Department of Anesthesia and Intensive Care Medicine

Turin, 10126, Italy

Location

MeSH Terms

Conditions

Respiratory InsufficiencyRespiratory Aspiration

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Pierpaolo Terragni, MD

    Department of Anesthesia and Intensive Care Medicine, University of Turin, Italy

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

August 21, 2014

First Posted

August 22, 2014

Study Start

July 1, 2014

Primary Completion

June 1, 2016

Study Completion

July 1, 2016

Last Updated

May 9, 2017

Record last verified: 2017-05

Locations